Day: June 27, 2023

CAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that its management team will participate in the SVB Securities Healthcare Therapeutics Forum, being held in New York, July 11-12, 2023. The Synlogic team will be available for one-on-one investor meetings. To register for the conference or request one-on-one meetings, please contact your SVB Securities representative. About Synlogic Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company’s late-stage pipeline is focused on rare metabolic diseases,...

Leading provider of SaaS-based marketing tools Utilizes Artificial Intelligence to Offer Industry-Leading Solutions BOCA RATON, Fla., June 27, 2023 (GLOBE NEWSWIRE) — springbig (the “Company”) (NASDAQ: SBIG), a leading provider of SaaS-based marketing solutions, today highlighted its use of artificial intelligence to align consumers, retailers and brands in this evolving era of business innovation. The Company launched its first artificial intelligence-based solution in April and today followed up with a new AI Assistant tool. springbig’s new AI Assistant is a new tool that allows cannabis retailers to leverage artificial intelligence to write engaging content for their email campaigns. The AI text generator powered by OpenAI’s language model, GPT-3.5, is a game-changer for businesses looking to improve email copy,...

Plug’s highly compact electrolyzer the first of its size to be installed offshore to generate green hydrogen LATHAM, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, is part of a consortium of companies that received a $21.8 million dollar grant from the European Commission to build an offshore hydrogen production plant. As a member of the nine-company consortium HOPE (Hydrogen Offshore Production Europe), Plug will design and deliver a 10-megawatt (MW) proton exchange membrane (PEM) electrolyzer system to the site in the North Sea, off the port of Ostend, Belgium. This 10MW offshore hydrogen project aims to prove the commercial sustainability of renewable offshore hydrogen production, with the end goal to enable the deployment...

No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of Study DSMB Recommendation Allows for Open EnrollmentMELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the independent Data Safety Monitoring Board (“DSMB”), which is overseeing the Company’s ongoing Phase 2 clinical trial to treat chronic lumbar disc disease (“cLDD”), unanimously recommended the continuation of BioRestorative’s study in accordance with the current version of the protocol with no changes. The treated patients will receive BRTX-100, a product formulated from autologous (or a person’s own) hypoxic cultured mesenchymal stem cells collected from the patient’s...

TORONTO, June 27, 2023 (GLOBE NEWSWIRE) — Latitude Uranium Inc. (“Latitude Uranium”, “LUR” or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) is pleased to announce it has changed its name from “Labrador Uranium Inc.” to “Latitude Uranium Inc.” to better reflect its expansion within Canada following its recently completed acquisition of the Angilak Property, located in Nunavut Territory, Canada. It is anticipated that the Company’s common shares (the “Common Shares”) will commence trading on the Canadian Securities Exchange (“CSE”) under the new name effective as of the open of markets in two or three business days. The Common Shares will continue to trade under the existing trading symbol “LUR”. The name change does not affect the rights of the Company’s securityholders. There is no consolidation or division of capital associated...

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has granted approval for Opfolda® (miglustat) 65mg capsules, an enzyme stabilizer of cipaglucosidase alfa, a long-term enzyme replacement therapy for adults with late-onset Pompe disease. Pombiliti® (cipaglucosidase alfa) was previously approved by the EC in March 2023. Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid α-glucosidase (GAA). Amicus plans to immediately launch Pombiliti + Opfolda in Germany...

LONDON, June 27, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Cancer Immunology Research1 entitled: ‘Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors.’ For CAR T cells to be effective, they must engraft in the patient, expand to sufficient numbers and persist at the site of disease. Often this can involve intervals in the absence of cognate antigen, for instance during trafficking, or in the face of a hostile tumor microenvironment. T cells in a physiological immune response are supported by a network of immune cells which provide cytokine signals to stimulate proliferation and survival. CAR T cells must survive in the absence of such...

BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutationsConfirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable disease Expansion cohorts expected to commence in second half of 2023 to assess ORR by RECIST 1.1 in NSCLC patients with EGFR-acquired resistance and intrinsic driver mutations after progression on...

CHICAGO and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) — RISE Dispensaries, a rapidly growing cannabis retail chain owned by Green Thumb Industries Inc. (“Green Thumb”) (CSE: GTII) (OTCQX: GTBIF), today announced that RISE Dispensary Danville, the Company’s 6th retail location in Virginia and 83rd nationwide, will open on June 28th. The new dispensary will host a grand opening event on July 15th, where profits from the day will be donated to Virginia NORML. The event will feature special discounts, music and treats, and the first 50 patients in line will receive 50% off their purchase, accompanied by a swag bag. “We are excited to expand our presence in Virginia and provide greater access to safe, high-quality cannabis products for medical patients in the area,” said Jack Page, Virginia Market Leader at Green Thumb....

Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024 TORONTO, June 27, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has filed a Pre-Submission Facility Correspondence in advance of its Abbreviated New Drug Application (“ANDA”) for KETARX™ (racemic ketamine) to the Food and Drug Administration (“FDA”) to support expedited review of its priority ANDA. The filing of a Pre-Submission Facility Correspondence will help achieve approval early compared to the standard ANDA approval times. The Company anticipates KETARX™ approval from the FDA as early as Q1-2024 and commercial launch in the U.S. in Q2-2024 followed...